Evidence map›Paper›PMID 40736647›Full record

ReviewDrugs2025

Acoltremon: First Approval.

Arnold Lee

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07502378 (Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07502378 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

TypeinterventionalSponsorUniversity of South FloridaRan2026 to 2027Enrolled50ConditionsOcular Surface Disease, Neurotrophic Keratopathy Stage 1ArmsPatients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternative would be patient exiting the trial and starting on tears or other standard of care.
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Arnold LeeSpringer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.ORCID http://orcid.org/0000-0002-6519-7831

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acoltremon (TRYPTYR

Indexed as

CyclohexenesDry Eye SyndromesOphthalmic SolutionsTRPM Cation ChannelsClinical Trials, Phase III as TopicDrug ApprovalHumansTearsacoltremonCyclohexenesOphthalmic SolutionsTRPM8 protein, humanTRPM Cation Channels

Identifiers

PMID40736647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.